This purpose of this study is
to determine the efficacy of humanized CD19 CAR  T cells (huCART19) in pediatric and young
adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic
leukemia (B-ALL). You may be eligible to participate if you are between the
ages of 1-29 years with CD19-expressing B-ALL that is refractory to
chemotherapy, has relapsed in the bone marrow <36 months from diagnosis,
relapsed more than once, or relapsed after bone marrow transplant or after
previous CAR T cell therapy. This study involves the administration of the
study drug, blood draws, assessment of leukemia response, chart reviews, and
questionnaires. Reimbursement for travel may be provided. If you have questions
or would like to learn more about the study, please contact the Cancer
Immunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. Shannon
Maude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.